Ignite Creation Date:
2025-12-24 @ 11:35 PM
Ignite Modification Date:
2026-01-01 @ 2:08 PM
Study NCT ID:
NCT03095456
Status:
COMPLETED
Last Update Posted:
2022-02-24
First Post:
2017-03-24
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
Sponsor:
Mylan Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-03-27
Start Date Type:
ACTUAL
Primary Completion Date:
2017-11-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-11-25
Completion Date Type:
ACTUAL
First Submit Date:
2017-03-24
First Submit QC Date:
None
Study First Post Date:
2017-03-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2018-12-06
Results First Submit QC Date:
None
Results First Post Date:
2018-12-31
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2018-09-25
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2022-02-22
Last Update Post Date:
2022-02-24
Last Update Post Date Type:
ACTUAL